Human Reproduction, Vol 13, 30-32, Copyright © 1998 by Oxford University Press
M Ludwig, O Bauer, A Lopens, W Jelkmann and K Diedrich
Vascular endothelial growth factor (VEGF) is stated to be a possible
promoter of the development and the severity of ovarian hyperstimulation
syndrome (OHSS). The secretion of VEGF in granulosa cells seems to be human
chorionic gonadotrophin (HCG) dependent. In this prospective study, the
data of 10 patients suffering from severe OHSS with ascites and pleural
effusions (haematocrit, fluid balance, serum HCG, serum oestradiol) were
analysed. The serum VEGF concentration declined during the period of
clinical improvement but provided no additional diagnostic information for
the further course of OHSS. VEGF was neither an early marker of
improvement, nor of worsening of the clinical picture of the OHSS. Serum
oestradiol concentrations and serum VEGF concentrations showed a
statistical correlation (r = 0.33, P < 0.001). There was no correlation
between haematocrit and VEGF, nor between serum HCG and VEGF. To conclude,
although VEGF may be involved in the pathogenesis of OHSS, it is not an
important clinical marker for the course of an OHSS.
ARTICLES
Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome
Department of Gynecology and Obstetrics, Medical University of Lubeck, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Villasante, A. Pacheco, E. Pau, A. Ruiz, A. Pellicer, and J.A. Garcia-Velasco Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome Hum. Reprod., March 1, 2008; 23(3): 662 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Manau, F. Fabregues, J. Penarrubia, M. Creus, F. Carmona, G. Casals, W. Jimenez, and J. Balasch Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF Hum. Reprod., March 1, 2007; 22(3): 669 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. McElhinney, J. Ardill, C. Caldwell, F. Lloyd, and N. McClure Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum. Reprod., June 1, 2002; 17(6): 1548 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.L. Benifla, A.F. Bringuier, C. Sifer, R. Porcher, P. Madelenat, and G. Feldmann Vascular endothelial growth factor, platelet endothelial cell adhesion molecule-1 and vascular cell adhesion molecule-1 in the follicular fluid of patients undergoing IVF Hum. Reprod., July 1, 2001; 16(7): 1376 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-D. Chen, H.-F. Chen, H.-F. Lu, S.-U. Chen, H.-N. Ho, and Y.-S. Yang Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome Hum. Reprod., May 1, 2000; 15(5): 1037 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ludwig, W. Jelkmann, O. Bauer, and K. Diedrich Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration Hum. Reprod., October 1, 1999; 14(10): 2437 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Doldi, A. Destefani, A. Gessi, D. Grossi, and A. Ferrari Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome Hum. Reprod., May 1, 1999; 14(5): 1157 - 1159. [Abstract] [Full Text] [PDF]
|
|